Want to see HK:1951 full AI Analyst Report?
1951 Stock Chart & Stats
HK$2.48
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$2.48
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.92 - HK$3.70
Previous CloseN/A
Volume13.42M
Average Volume (3M)20.30M
Market Cap
HK$5.44B
Enterprise ValueHK$6.77B
Total Cash (Recent Filing)HK$906.17M
Total Debt (Recent Filing)HK$2.96B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Sep 01, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend Yield2.38%
Share Statistics
EPS (TTM)-0.36
Shares Outstanding2,705,044,000
10 Day Avg. Volume21,878,483
30 Day Avg. Volume20,304,545
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.00Price Target Upside20.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.85B
Bulls Say, Bears Say
Bulls Say
Manageable LeverageBalance sheet leverage at roughly 0.25–0.32 provides durable financial flexibility. Lower leverage reduces refinancing risk, supports funding clinic operations or selective expansion, and cushions the firm against earnings volatility, preserving strategic optionality over months to years.
Consistent Operating Cash FlowSustained positive operating cash flow supports day-to-day operations and investment without reliance on external financing. This cash generation helps absorb temporary earnings swings, funds working capital and necessary capex in clinics, and underpins medium-term operational resilience.
High EBITDA Margin & Clinic NetworkA roughly 21% EBITDA margin combined with a network of fertility hospitals implies structural operating efficiency and scale advantages. Durable margin and clinic footprint support pricing power, repeat patient flows and the ability to allocate fixed costs across volumes over the coming months.
Bears Say
2025 Revenue Decline And Large Net LossA revenue decline and a swing to a substantial net loss in 2025 indicate material deterioration in core profitability. This weakens retained earnings, constrains reinvestment capacity, and may require structural cost actions; such earnings reversals can impede recovery and strategic initiatives over several quarters.
Declining Free Cash FlowA sizable drop in free cash flow reduces financial flexibility for investment or acquisitions and increases reliance on external funding. Persistently weaker FCF limits the firm's ability to absorb shocks, fund clinic upgrades, or rebuild buffers, raising medium-term execution risk if trends persist.
Negative Return On EquityA negative ROE signals the business is currently destroying shareholder capital rather than creating it. This undermines investor confidence, may pressure management for restructuring or capital raises, and complicates long-term access to equity funding if profitability does not recover.
Jinxin Fertility Group Ltd. News
1951 FAQ
What was Jinxin Fertility Group Ltd.’s price range in the past 12 months?
Jinxin Fertility Group Ltd. lowest stock price was HK$1.92 and its highest was HK$3.70 in the past 12 months.
What is Jinxin Fertility Group Ltd.’s market cap?
Jinxin Fertility Group Ltd.’s market cap is HK$5.44B.
When is Jinxin Fertility Group Ltd.’s upcoming earnings report date?
Jinxin Fertility Group Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 60 days.
How were Jinxin Fertility Group Ltd.’s earnings last quarter?
Jinxin Fertility Group Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.035 earnings per share for the quarter, the consensus estimate of HK$0.035 by HK$0.
Is Jinxin Fertility Group Ltd. overvalued?
According to Wall Street analysts Jinxin Fertility Group Ltd.’s price is currently Undervalued.
Does Jinxin Fertility Group Ltd. pay dividends?
Jinxin Fertility Group Ltd. pays a Annually dividend of HK$0.042 which represents an annual dividend yield of 2.38%. See more information on Jinxin Fertility Group Ltd. dividends here
What is Jinxin Fertility Group Ltd.’s EPS estimate?
Jinxin Fertility Group Ltd.’s EPS estimate is 0.03.
How many shares outstanding does Jinxin Fertility Group Ltd. have?
Jinxin Fertility Group Ltd. has 2,705,044,000 shares outstanding.
What happened to Jinxin Fertility Group Ltd.’s price movement after its last earnings report?
Jinxin Fertility Group Ltd. reported an EPS of HK$0.035 in its last earnings report, expectations of HK$0.035. Following the earnings report the stock price went up 2.681%.
Which hedge fund is a major shareholder of Jinxin Fertility Group Ltd.?
Currently, no hedge funds are holding shares in HK:1951
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jinxin Fertility Group Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.67%
12-Months-Change
Fundamentals
Return on Equity
-10.66%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Jinxin Fertility Group Ltd.
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial insemination, which can be performed using either the husband's or a donor's sperm, and advanced in vitro fertilization (IVF) technologies, ranging from conventional IVF with embryo transfer to IVF utilizing intracytoplasmic sperm injection (ICSI). To complement its ARS treatments, the company also furnishes a range of supportive services such as nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Beyond fertility-specific care, Jinxin Fertility Group extends its operations to include management services, general medical care encompassing gynecology, urology, and internal medicine, as well as ambulatory surgery center facilities and other ancillary medical services. Furthermore, the company conducts pre-implantation genetic screening tests. Its business scope also diversifies into investment management, management consulting, and real estate development and operation. Jinxin Fertility Group Limited was established in 2003 and has its corporate headquarters located in Chengdu, China.
1951 Stock 12 Month Forecast
Average Price Target
HK$3.00
▲(20.97% Upside)
Technical Analysis
Aidigong Maternal & Child Health
―
Kindstar Globalgene Technology, Inc.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Concord Healthcare Group Co., Ltd. Class H
―
Options Prices
Currently, No data available
---